Matching AML therapy to genetics and fitness boosts survival in seniors
NCT ID NCT03226418
First seen Nov 06, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study looked at whether tailoring chemotherapy for older adults (60+) with acute myeloid leukemia (AML) based on their genetic profile and overall health can improve outcomes. 75 participants received either standard intensive or milder therapy based on these factors. The goal was to see if this personalized approach could increase remission rates and reduce early death, while also tracking quality of life and survival over two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.